Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -45.51% | -11.91% | 26.58% | -25.88% | 35.94% |
Total Depreciation and Amortization | 31.90% | 24.33% | 32.28% | -2.33% | 10.24% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 65.73% | 472.61% | 170.54% | 129.44% | -72.80% |
Change in Net Operating Assets | 48.12% | -382.85% | -89.69% | -1,769.84% | -392.92% |
Cash from Operations | -8.05% | 2.18% | -0.13% | -71.41% | -80.15% |
Capital Expenditure | -1,438.89% | -2,385.29% | 10.32% | -340.63% | -71.43% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -1,038.98% | -2,385.29% | 11.34% | -340.63% | 380.95% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | 100.00% | -22,906.50% | -128,917.14% |
Issuance of Common Stock | -- | -98.15% | 120,550.57% | -100.00% | -100.00% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 105.31% | -98.14% | 528,751.67% | -128.25% | -198.36% |
Foreign Exchange rate Adjustments | 239.01% | 120.72% | -262.17% | 192.84% | -317.86% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 38.93% | -134.09% | 568.04% | -244.51% | -2,643.20% |